ADAMTSL5 Is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab
Open accessAbstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Th9 cell frequency is significantly increased in patients responding to anti-PD-1 treatment.
“Th9 CD4+ T cells have also been suggested to play a role according to a recent study that detected a significant increase in Th9 cell frequency in patients responding to anti-PD-1 treatment (91, 92).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [91]
Cites
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Melanocyte antigen triggers autoimmunity in human psoriasis
Arakawa, A., Siewert, K., Stöhr, J., Besgen, P., Kim, S.-M., Rühl, G., Nickel, J., Vollmer, S., Thomas, P. T., Krebs, S., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151093 · Cited by 361 · see citing works
Analysis of the Paired TCR α- and β-chains of Single Human T Cells
Kim, S.-M., Bhonsle, L., Besgen, P., Nickel, J., Backes, A., Held, K., Vollmer, S., Dornmair, K., & Prinz, J. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037338 · Cited by 107 · see citing works
Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
Matsumura, N., Ohtsuka, M., Kikuchi, N., & Yamamoto, T. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2212 · Cited by 99 · see citing works
Self-citationOccurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma
Ohtsuka, M., Miura, T., Mori, T., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0249 · Cited by 95 · see citing works
Self-citationExacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma
Kato, Y., Otsuka, A., Miyachi, Y., & Kabashima, K. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13336 · Cited by 85 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works
Self-citationImmune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works
- Authors
- Nonomura, Y., Otsuka, A., Ohtsuka, M., Yamamoto, T., Dummer, R., & Kabashima, K.
- Affiliations
- Kyoto University (JP)
- Fukushima Medical University (JP)
- University Hospital Zurich (CH)
- Agency for Science, Technology and Research (SG)
- Corresponding author
- Otsuka, A.
- Kabashima, K.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2016-07-27
- Volume
- 31
- Issue
- 2
- Pages
- e100-e101
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W2480993280
- Cited by
- 19
- References
- 6
- Citations by year
- 2024: 2 · 2022: 3 · 2021: 2 · 2020: 2 · 2018: 5 · 2017: 5
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Journal of the European Academy of Dermatology and Venereology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- melanoma, nivolumab, gene upregulation
- MeSH terms
- ADAMTS Proteins, Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Melanoma, Psoriasis, Up-Regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
